Clinical Trial Update: A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension [Phase 3]

View source ↗

Summary

A multicenter Phase 3 study evaluated the antihypertensive efficacy and safety of fimasartan 30 mg versus placebo in adults with mild to moderate essential hype…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Fimasartan (fimasartan)

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Hypertension | Phase 3 | Status: COMPLETED